<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04164459</url>
  </required_header>
  <id_info>
    <org_study_id>TJO-002-401</org_study_id>
    <nct_id>NCT04164459</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.</brief_title>
  <official_title>A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase IV Study to Evaluate the Efficacy and Safety of Xalost S in Glaucoma Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taejoon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taejoon Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with Glaucoma, Xalost S or Xalatan or Taflotan-S are administered for 12 weeks.
      After 12 weeks, among them, Xalatan administration group are switched to Xalost S or
      Taflotan-S. Extension study period is 8 weeks.

      To compare effect (ocular surface damage) and safety of preservative-free
      Latanoprost/Tafluprost to Benzalkonium chloride-preserved Latanoprost in primary open angle
      glaucoma or normal tension glaucoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2018</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal Staining Score at week 12</measure>
    <time_frame>week 12</time_frame>
    <description>At week 12 of drug administration compare the therapeutic effectiveness between control drug and trial drug evaluated as the effect on corneal staining score.
Scale: &quot;Oxford grading system&quot; that divides into 6 groups according to severity from 0 (absent) to 5 (severe).
The higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hyperemia Score at week 4, 8, 12</measure>
    <time_frame>baseline and week 4, 8, 12</time_frame>
    <description>After 4, 8, 12 weeks of drug administration compare the therapeutic effectiveness between control drug and trial drug evaluated as the effect on Hyperemia Score.
Scale: &quot;Efron Grading Scales&quot; that divided into 5 groups according to severity from 0 (normal) to 4 (severe).
The higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Intraocular Pressure at week 4, 8, 12</measure>
    <time_frame>baseline and week 4, 8, 12</time_frame>
    <description>After 4, 8, 12 weeks of drug administration compare the therapeutic effectiveness between control drug and trial drug evaluated as the effect on Intraocular pressure.
The highest Intraocular pressure means a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Xalost S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Xalatan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Taflotan-S</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xalost S</intervention_name>
    <description>One drop one times a day in study eye</description>
    <arm_group_label>Xalost S</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xalatan</intervention_name>
    <description>One drop one times a day in study eye</description>
    <arm_group_label>Xalatan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taflotan-S</intervention_name>
    <description>One drop one times a day in study eye</description>
    <arm_group_label>Taflotan-S</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female diagnosed with glaucoma, age 19 or over

          -  Written informed consent to participate in the trial

        Exclusion Criteria:

          -  Patients who have received or have plans lacrimal puntual occulsion

          -  Use of contact lenses

          -  Any other Glaucoma except primary open angle glaucoma/normal tension glaucoma (ex)
             Closed anterior chamber angle/ angle-closure Glaucoma)

          -  Any condition limiting patient's ability to participate in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sukyoung Kwon, PhD</last_name>
    <phone>+82-2-799-0175</phone>
    <email>skkwon@taejoon.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taejoon Pharmaceutical Co., Ltd.</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

